Compare Morphine and Dexmedetomidine as Adjuvants to Bupivacaine in Ultrasound-guided ACB for Postoperative Analgesia After Knee Surgeries

NCT ID: NCT07240402

Last Updated: 2025-11-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE1/PHASE2

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-11-17

Study Completion Date

2026-02-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to compare morphine and dexmedetomidine as adjuvants to bupivacaine in ultrasound-guided ACB for postoperative analgesia after knee surgeries

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Knee surgeries are frequently performed operations that can lead to intense pain after the procedure (1). Early mobilization following knee surgery is associated with improved functional outcomes and a reduction in postoperative complications. As a result, achieving effective pain relief while preserving motor function is a primary goal in postoperative care for knee procedures (2).

A variety of strategies are employed for managing postoperative pain, including systemic opioid administration, epidural anesthesia, peripheral nerve blocks, and local infiltration of anesthetics (3).

However, systemic opioids are linked to several undesirable side effects such as nausea, vomiting, itching, sedation, and respiratory depression, which may hinder rehabilitation.

Similarly, epidural analgesia often results in complications like hypotension, urinary retention, and pruritus. The use of long-acting intrathecal opioids has also been associated with adverse events including bilateral motor blockade, tremors, and hypotension. Due to these issues, the reliance on systemic and intrathecal methods for postoperative pain control has been declining (4).

The adductor canal block (ACB), which targets the Hunter's canal, anesthetizes the saphenous and vastus medialis nerves, along with partial coverage of other sensory nerves like the femoral nerve, medial cutaneous nerve, and branches of the obturator nerve as they traverse the distal canal (5). ACB is largely considered a sensory block, affecting only the motor nerve to the vastus medialis, making it advantageous in preserving quadriceps strength during recovery (6, 7). Bupivacaine, a widely used long-acting amide local anesthetic, is frequently employed in peripheral nerve blocks such as the ACB due to its favorable pharmacokinetics.

Nonetheless, its analgesic duration may be insufficient for managing postoperative pain in surgeries with high nociceptive intensity (8). To extend its efficacy and enhance analgesic quality, several adjunctive agents have been explored, including opioids and α2-adrenergic agonists (9).

Morphine, a traditional opioid analgesic, acts on μ-opioid receptors to prolong analgesia and reduce local anesthetic requirements. Despite its effectiveness, its use is limited by opioid-related adverse effects like nausea, vomiting, pruritus, and respiratory depression. Furthermore, some studies report that morphine may not significantly improve postoperative pain control or functional recovery after knee surgery (10-12).

Dexmedetomidine, a highly selective α2-adrenergic receptor agonist, has been increasingly studied as an adjuvant in peripheral nerve blocks. When administered

perineurally, it has demonstrated potential to accelerate onset, prolong analgesia, reduce postoperative pain intensity, and minimize systemic opioid use, all while producing fewer systemic side effects (13). Its peripheral analgesic properties are thought to result from direct binding to α2-receptors at the nerve site (14).

Currently, there is limited research directly comparing the efficacy of morphine versus dexmedetomidine as adjuvants to bupivacaine in ultrasound-guided ACB for postoperative analgesia following knee surgeries.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Postoperative Analgesia Morphine and Dexmedetomidine

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group D

Patients will receive ACB using 20 ml of bupivacaine 0.25%+ 0.5 µg/kg dexmedetomidine.

Group Type EXPERIMENTAL

Adductor Canal Block (ACB) Only

Intervention Type DRUG

This study aims to compare morphine and dexmedetomidine as adjuvants to bupivacaine in ultrasound-guided ACB for postoperative analgesia after knee surgeries. Primary outcome:

• Time to first rescue analgesia .

Secondary outcomes:

* Total opioid consumption in 24 hours postoperatively.
* Degree of pain using visual analogue scale (VAS).
* Degree of patient satisfaction.
* Incidence of complication A) Related to block Nerve Injury Vascular Puncture Hematoma B) Related to drug Local Anesthetic Systemic Toxicity (LAST)

Group M

Patients will receive ACB using 20 ml of bupivacaine 0.25%

+0.1 mg/kg morphine.

Group Type EXPERIMENTAL

Adductor Canal Block (ACB) Only

Intervention Type DRUG

This study aims to compare morphine and dexmedetomidine as adjuvants to bupivacaine in ultrasound-guided ACB for postoperative analgesia after knee surgeries. Primary outcome:

• Time to first rescue analgesia .

Secondary outcomes:

* Total opioid consumption in 24 hours postoperatively.
* Degree of pain using visual analogue scale (VAS).
* Degree of patient satisfaction.
* Incidence of complication A) Related to block Nerve Injury Vascular Puncture Hematoma B) Related to drug Local Anesthetic Systemic Toxicity (LAST)

Group C

Patients will receive ACB using 20 ml of bupivacaine 0.25% alone as a control group.

Group Type EXPERIMENTAL

Adductor Canal Block (ACB) Only

Intervention Type DRUG

This study aims to compare morphine and dexmedetomidine as adjuvants to bupivacaine in ultrasound-guided ACB for postoperative analgesia after knee surgeries. Primary outcome:

• Time to first rescue analgesia .

Secondary outcomes:

* Total opioid consumption in 24 hours postoperatively.
* Degree of pain using visual analogue scale (VAS).
* Degree of patient satisfaction.
* Incidence of complication A) Related to block Nerve Injury Vascular Puncture Hematoma B) Related to drug Local Anesthetic Systemic Toxicity (LAST)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Adductor Canal Block (ACB) Only

This study aims to compare morphine and dexmedetomidine as adjuvants to bupivacaine in ultrasound-guided ACB for postoperative analgesia after knee surgeries. Primary outcome:

• Time to first rescue analgesia .

Secondary outcomes:

* Total opioid consumption in 24 hours postoperatively.
* Degree of pain using visual analogue scale (VAS).
* Degree of patient satisfaction.
* Incidence of complication A) Related to block Nerve Injury Vascular Puncture Hematoma B) Related to drug Local Anesthetic Systemic Toxicity (LAST)

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

adductor canal block

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Both sexes.
* American Society of Anesthesiologists (ASA) physical status I-II.
* Body mass index (BMI) of 20-35 kg/m2.
* Undergoing knee surgeries under spinal anesthesia.

Exclusion Criteria

* Any known allergy or contraindication to local anesthetic.
* History of substance abuse.
* Decompansated cardiac, pulmonary, hepatic, renal disease.
* Obese patients with BMI\>35kg/m2.
* Pregnant and lactating mothers.
* Coagulopathies.
* Local skin infections at the site of injection.
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Kafrelsheikh University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ashraf Abd El-Nasser Abd El-Hamid

Ashraf Elrewany

Responsibility Role PRINCIPAL_INVESTIGATOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ashraf Abd El-Nasser Abd El-Hamid kamel El Rewany Anesthesia KafrElsheikh University Faculty of Medicine Anesthesia, Surg, MBBCH

Role: CONTACT

+201061195395

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

KafrelsheikhU

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.